Jaguar Health converts $22.7M royalty debt to preferred equity with creditor veto rights

Filed May 19, 2026 · Period ending May 19, 2026 · ~2 min read

Key Changes

• high

  Issued 908 shares of new Series Q Preferred Stock to eliminate $22.7M in royalty obligations to Uptown Capital ($12.5M) and Streeterville Capital ($10.2M), converting revenue-based payments into equity claims with 10% annual accreting return.

  Item 1.01 verify on EDGAR →
• high

  Series Q holders gain veto rights over asset sales, reverse splits, new preferred issuances, fundamental transactions, and equity raises exceeding $15M, significantly restricting management's operational flexibility.

  Item 5.03 verify on EDGAR →
• high

  Series Q carries $25,000 stated value per share with liquidation preference over common stock plus accrued 10% return; upon default, holders can force redemption into common stock at floor price of $0.726, risking severe dilution.

  Item 5.03 verify on EDGAR →